Healthy longevity-associated protein improves cardiac function in murine models of cardiomyopathy with preserved ejection fraction.

Valeria Vincenza Alvino, Sadie Slater, Yan Qiu, Monica Cattaneo, Khaled Abdelsattar Kassem Mohammed, Seamus Gate, Vealmurugan Sekar, Annibale Alessandro Puca, Paolo Madeddu

Bristol Medical School, Translational Health Sciences, University of Bristol, Upper Maudlin St, Bristol, BS2 8HW, UK.Bristol Medical School, Translational Health Sciences, University of Bristol, Upper Maudlin St, Bristol, BS2 8HW, UK. · pubmed

Paper

Abstract

Aging is influenced by genetic determinants and comorbidities, among which diabetes increases the risk for heart failure with preserved ejection fraction. There is no therapy to prevent heart dysfunction in aging and diabetic individuals. In previous studies, a single administration of the longevity-associated variant (LAV) of the human BPIFB4 gene halted heart decline in older and type 2 diabetic mice. Here, we asked whether orally administered LAV-BPIFB4 protein replicates these benefits.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper investigates the effects of a longevity-associated protein on cardiac function in murine models, which aligns with the broader goals of longevity research by addressing potential interventions that could mitigate age-related cardiac decline. However, while the findings may contribute to understanding the mechanisms of aging and heart function, they appear to be an incremental advance rather than a groundbreaking discovery, thus warranting a moderate impact score.

Author of this paper? Send a correction.